Qu Biologics Closes Oversubscribed Financing; Crohn's Disease Phase 2 Clinical Trial Results in First Quarter 2016

Corporate Breaking News

Home : Qu Biologics Closes Oversubscribed Financing; Crohn's Disease Phase 2 Clinical Trial Results in First Quarter 2016

Dec 24 2015	Qu Biologics Closes Oversubscribed Financing; Crohn's Disease Phase 2 Clinical Trial Results in First Quarter 2016
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 23, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's normal immune response, announced it has closed an oversubscribed private financing of CDN$3.5 million bringing the total private equity capital raised to CDN$19 million to date.


Source:http://www.marketwired.com/mw/release.do?id=2084336&sourceType=3

Related News
» Talisman Energy Inc. Announces Latest Results of Its Debt Tender Offer, Increase to the Maximum Tender Amount, and Extension of Expiration Date » Driver Accused in Deadly Vegas Crash Appears in Court